logo

Blogs

The 8 Market Access Performance Metrics You Should Be Tracking

The 8 Market Access Performance Metrics You Should Be Tracking

Here Are 8 Essential KPIs Your Market Access Teams Should Be Looking At The route to market for any given drug is rarely a straight line. There are many obstacles to overcome and expectations are high. You need to achieve the best price and broadest possible access in the shortest possible time across the greatest […]

GETTING MORE OUT OF YOUR ANALOGUE ASSESSMENTS WITH NURO

GETTING MORE OUT OF YOUR ANALOGUE ASSESSMENTS WITH NURO

‘What pricing opportunities do I have when launching in a highly genericised landscape?’

‘What does differentiation look like in a crowded market place?’

THE UPS AND DOWNS OF CIPM PRICE REVISIONS

THE UPS AND DOWNS OF CIPM PRICE REVISIONS

The Spanish healthcare system is notorious for being cost-conscious. With COVID-19 acting as a major setback in terms of budget allocation and public debt (1), this could have consequential knock-on effects on Spain’s willingness to pay for drugs.

MARKET ACCESS IS EASY, THERE ARE ONLY 5 STEPS

MARKET ACCESS IS EASY, THERE ARE ONLY 5 STEPS

As we welcome our 6th director to Access Infinity and take our collective market access experience to well over a century, we have been thinking about what sets us apart as a market access consultancy.

BALANCING A FASTER TIME TO LAUNCH VS OPTIMAL ACCESS: CONDITIONAL MARKETING AUTHORISATION AND HTA BODIES

BALANCING A FASTER TIME TO LAUNCH VS OPTIMAL ACCESS: CONDITIONAL MARKETING AUTHORISATION AND HTA BODIES

Generating comprehensive data in rare diseases or chronic progressive conditions, can be challenging often requiring lengthy study durations and very high investment. The European Medicines Agency (EMA) therefore considers granting early market authorisation of a product for seriously debilitating, life-threatening, or rare diseases. Given the current global climate from challenges posed by COVID-19, even more interest has […]

HOW GARDASIL RESHAPED THE VACCINES MARKET

HOW GARDASIL RESHAPED THE VACCINES MARKET

‘What pricing opportunities do I have when launching in a highly genericised landscape?’

‘What does differentiation look like in a crowded market place?’